Pro-Dex Q4 EPS Lifted by Ascendiant Capital Markets

Pro-Dex, Inc. (NASDAQ:PDEX) – Equities research analysts at Ascendiant Capital Markets increased their Q4 2027 earnings per share estimates for shares of Pro-Dex in a report released on Thursday, September 10th. Ascendiant Capital Markets analyst E. Woo now anticipates that the medical instruments supplier will earn $0.87 per share for the quarter, up from their prior estimate of $0.70. Ascendiant Capital Markets has a “Buy” rating and a $74.00 price target on the stock. The consensus estimate for Pro-Dex’s current full-year earnings is $3.09 per share.

Pro-Dex (NASDAQ:PDEX) last announced its quarterly earnings data on Thursday, September 3rd. The medical instruments supplier reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.20. The firm had revenue of $20.40 million during the quarter, compared to analysts’ expectations of $19.20 million. Pro-Dex had a return on equity of 25.13% and a net margin of 17.62%.

PDEX has been the topic of a number of other reports. Zacks Research upgraded Pro-Dex from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Weiss Ratings upgraded shares of Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, September 4th. Finally, Wall Street Zen upgraded shares of Pro-Dex from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat, Pro-Dex presently has a consensus rating of “Buy” and an average target price of $74.00.

Pro-Dex Price Performance

Shares of NASDAQ:PDEX opened at $71.85 on Thursday. The company has a quick ratio of 2.45, a current ratio of 4.10 and a debt-to-equity ratio of 0.28. Pro-Dex has a twelve month low of $23.47 and a twelve month high of $77.00. The stock’s 50 day moving average is $62.92 and its 200-day moving average is $58.37. The firm has a market capitalization of $229.92 million, a price-to-earnings ratio of 17.40 and a beta of 0.06.

Hedge Funds Weigh In On Pro-Dex

Large investors have recently bought and sold shares of the stock. Navellier & Associates Inc. bought a new stake in shares of Pro-Dex in the 2nd quarter worth $322,000. Bank of New York Mellon Corp bought a new position in shares of Pro-Dex during the second quarter valued at about $678,000. Corsair Capital Management L.P. bought a new position in shares of Pro-Dex during the first quarter valued at about $532,000. Punch & Associates Investment Management Inc. boosted its holdings in Pro-Dex by 2.9% during the first quarter. Punch & Associates Investment Management Inc. now owns 61,735 shares of the medical instruments supplier’s stock worth $3,032,000 after purchasing an additional 1,735 shares during the last quarter. Finally, Morgan Dempsey Capital Management LLC boosted its holdings in Pro-Dex by 6.2% during the first quarter. Morgan Dempsey Capital Management LLC now owns 5,808 shares of the medical instruments supplier’s stock worth $286,000 after purchasing an additional 339 shares during the last quarter. 15.28% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CFO Alisha Charlton sold 2,300 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $61.30, for a total value of $140,990.00. Following the completion of the sale, the chief financial officer directly owned 21,870 shares of the company’s stock, valued at $1,340,631. This represents a 9.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kirk Richard Lee Van, Jr. sold 765 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $59.36, for a total value of $45,410.40. Following the completion of the transaction, the chief executive officer owned 79,228 shares in the company, valued at $4,702,974.08. This represents a 0.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 22,300 shares of company stock valued at $1,351,657 over the last three months. Corporate insiders own 45.90% of the company’s stock.

Pro-Dex News Summary

Here are the key news stories impacting Pro-Dex this week:

• Positive Sentiment: Ascendiant raised its FY2027 EPS forecast to $3.09 from $2.78, while increasing estimates for Q1, Q2, and Q3 2027. The firm also lifted its Q4 2027 forecast to $0.87 from $0.70, signaling expectations for stronger profitability at the medical-instruments supplier.
• Positive Sentiment: Ascendiant maintained a Buy rating and a $74 price target. Its longer-term projections call for FY2028 EPS of $3.36, with quarterly estimates ranging from $0.77 to $0.91.
• Positive Sentiment: The revised FY2027 outlook is above the previously cited $2.78 consensus estimate, which may reinforce the view that Pro-Dex’s earnings momentum is improving.

Pro-Dex Company Profile

Pro-Dex, Inc is a medical device manufacturer that designs, develops and produces powered surgical instruments and related equipment. The company primarily serves original equipment manufacturers (OEMs), which incorporate Pro-Dex products into surgical systems sold under their own brands.

Its product portfolio includes battery-powered and electric handpieces, controllers, drivers, saws, microdebriders and other precision instruments used in medical and dental procedures. Pro-Dex also provides related components and accessories, including batteries, chargers and instrument controls, as well as engineering, manufacturing and product-development support for its customers.

Based in Irvine, California, Pro-Dex serves customers in the United States and international markets.